UBS Maintains Dexcom (DXCM) Buy Recommendation
Nasdaq Fintel reports that on September 6, 2023, UBS maintained coverage of Dexcom (NASDAQ:DXCM) with a Buy recommendation.
Analyst Price Forecast Suggests 51.85% Upside
As of August 31, 2023, the average one-year price target for Dexcom is 152.36. The forecasts range from a low of 131.30 to a high of $183.75. The average price target represents an increase of 51.85% from its latest reported closing price of 100.33.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Dexcom is 3,546MM, an increase of 10.90%. The projected annual non-GAAP EPS is 1.10.
What is the Fund Sentiment?
There are 1920 funds or institutions reporting positions in Dexcom. This is an increase of 19 owner(s) or 1.00% in the last quarter. Average portfolio weight of all funds dedicated to DXCM is 0.46%, a decrease of 1.79%. Total shares owned by institutions increased in the last three months by 0.37% to 437,989K shares. The put/call ratio of DXCM is 1.15, indicating a bearish outlook.